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Lactococcus lactis and its course
towards medical translation
Julio Villatoro-Hernandez†, Roberto Montes-de-Oca-Luna &
Oscar P Kuipers
†University of Groningen, Groningen Biomolecular Sciences and Biotechnology Institute,
Molecular Genetics Group, Haren, The Netherlands
The use of the lactic acid bacterium Lactococcus lactis, primarily used in food
fermentations, as therapeutic agent is no longer speculative but an imminent
reality. After the successful completion of Phase I and II clinical trials in
humans for the treatment of inflammatory bowel disease, an ongoing clinical
trial to alleviate oral mucositis as well as the development of a pneumococcal
and a flu vaccine using genetically modified L. lactis, many exciting possibili-
ties exist to develop novel therapeutic and prophylactic biopharmaceuticals
to alleviate a wide range of diseases. Here, we discuss existing characteristics
of the systems currently employed and the nature of the immune responses
evoked. We also discuss the criteria that are fundamental to making the sys-
tems feasible and efficient which should ultimately translate into human ther-
apies. Finally, we examine the prospects for L. lactis to become a commercially
viable therapeutic agent.
Keywords: biopharmaceuticals, human therapy, Lactococcus lactis, vaccine
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1. Introduction
Recent reviews have described early and contemporary achievements in the use of
the lactic acid bacterium (LAB) Lactococcus lactis as a therapeutic agent for different
human diseases and for the delivery of biologically active immunomodulating
proteins in vivo [1-3]. The results presented in these reports provide solid evidence
supporting the appropriate use of genetically engineered L. lactis to target diseases
and modulate immune responses. Two distinctions must be made in this
aspect. The first is the development of a L. lactis able to produce a specific antigen,
hence, regarded as a ‘vaccine’. The second is the production of a non-antigenic
immunomodulatory protein by L. lactis (e.g., cytokines) to stimulate the
immune system.
One of the earliest reports regarding L. lactis as a vehicle to elicit immune
responses describes the genetic manipulation of strain IL1403 (previously referred
to as Streptococcus lactis) to express the surface protein antigen (Pac) of Streptococcus
mutans. The resulting genetically modified organism (GMO) was then used to
immunize mice. Analysis of salivary and serological samples revealed the presence
of IgA and IgG in salivary secretions and in serum, which where specifically reactive
against S. mutans [4]. These and other studies explored the suitability of L. lactis in
the development of (live or dead) vaccines. Although other approaches using
pathogenic microorganisms, for example. Salmonella or Listeria species [5], were
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providing promising results in the induction of immune
responses, there was a much more keen interest in Lactococcus
because of its natural non-pathogenic and non-colonizing
properties [2]. Such an approach eliminated the drawbacks of
using pathogenic or nocuous attenuated microorganisms
that is the high risk and infeasible use in humans and in
clinical trials.
Presently, there is a vast collection of reports evidencing the
safe and effective use of L. lactis, firstly to produce a wide vari-
ety of proteins and peptides efficiently, but most importantly,
to deliver these biologically active molecules in vivo without
disturbing their specific activity [2,3].
In 2006, the first breakthrough in the application of
L. lactis in humans was reported, with Braat and colleagues
revealing a clinical approach to treat Crohn’s Disease with
an IL-10-secreting L. lactis. In the investigation they showed
that the oral administration of IL-10-secreting L lactis in
patients suffering from this disease resulted in a reduction of
the intestinal lesions and a consequent alleviation of the ill-
ness [6]. As an added safeguard to ensure limited survival of
the IL-10-expressing L. lactis once is released in the environ-
ment, the heterologous gene allowing for IL-10 expression
substituted an essential gene, thymidylate synthase (thyA).
The survival of this thyA-deficient GMO depends on the pres-
ence of thymidine or thymine in the growth medium. In this
way, the microorganism can be regarded as ‘biologically
contained’ [7]. This study, along with others, paved the path
for many other investigators into translational applica-
tions of existing strains of L lactis for the treatment of
other diseases.
While L. lactis possesses many characteristics such as easy
genetic manipulation and a long history of safe use in food,
that make it an attractive choice for further medical applica-
tions, the focus has been on fermenting LAB with the ability
to produce heterologous antigens rather than the optimization
of this bacterium for use as a vaccine.
1.1 Cellular antigen location in L. lactis
The location of the antigen is important for its immune-
modulating activity. For certain proteins, such as cytokines
or antibody fragments, extracellular secretion is necessary
due to their activity [7,8], whereas for other antigens it is
unclear whether the antigen must be produced extracellu-
larly, retained in the cytoplasm or attached to the cell wall.
Several factors influence whether intracellular or extracellular
localization is desirable. These include the nature of the
protein, that is its folding, accumulation and toxicity for
the producing cell and unwanted processing by cellular/
membrane-located proteases. However, most important is
the capability of the produced antigen to undergo the crucial
antigen processing by the immune machinery to ultimately
cause the desired specific (humoral and/or cellular) immune
response in the host. In this regard, there is an ongoing
debate among researchers to select the final location of the
L. lactis expressed-antigen. In several studies, immunization
with L. lactis expressing an intracellularly localized antigen
caused protection in mice when they were challenged with
the respective pathogen. In one such study, Hannify et al.
demonstrated that intranasal immunization with a strain of
L. lactis producing intracellularly-localized pneumococcal
surface protein A (PspA) from Streptococcus pneumoniae,
was able to cause protection in the immunized group when
they were challenged with S. pneumoniae, the causal agent
of pneumonia [9]. In another study, three strains of L. lactis
(all derived from L. lactis NZ9000 [10]) were developed
that were able to produce the E7 antigen of the human
papilloma virus type 16 (HPV-16) at different cellular loca-
tions, that is intracellular, secreted and attached to the cell
wall. After immunization of three groups of mice with the
three strains, it was demonstrated that L. lactis with the
E7 antigen attached to the cell wall displayed the highest
immunogenicity as compared with the other two strains,
even though equal amounts of E7 were produced by each
strain [11]. There are many other examples of the effect of
antigen location and immunogenicity and the reader is
referred to a recent review [3].
Vaccination using different mucosal surfaces may cause a
systemic production of IgA at different mucosal locations.
In this regard it seems remarkable that nasal mucosal immuni-
zation not only stimulates an immune response in the respira-
tory tract, but can also give rise to a strong genital--vaginal
mucosal immune response [12].
Article highlights.
. Genetically modified Lactococcus lactis are currently
being used to treat a variety of diseases. With the
increasing number of clinical trials and applications,
L. lactis has the potential to become a commercially
available biopharmaceutical in the coming years.
. Several aspects affect the efficacy of L. lactis vaccines.
The choice of antigen to be expressed by L. lactis, the
natural attributes and composition of the antigen, the
final cellular localization in L. lactis, as well as the route
of vaccine administration are all important factors which
need to be considered.
. The safety of administration of genetically manipulated
L. lactis to humans must be thoroughly assessed.
Deletion of essential genes or auxotrophic strains
prevent long-lasting viable cells and undesired
cell proliferation.
. Oral administration of genetically engineered L. lactis
able to produce IL-10 is currently being employed to
treat inflammatory bowel disease in humans (Crohn’s
Disease). This same strain is currently in clinical trials to
treat moderate ulcerative colitis and oral mucositis.
. Improving protein production by synthetic biology and
facilitating the antigen reaching the immune system are
viable options to create a better immune response of
the therapeutic agent.
This box summarizes key points contained in the article.
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Therefore, it is highly relevant to study the nature of the
antigen to be expressed by L. lactis (the candidate to create
the vaccine) to determine the most suitable cellular compart-
ment where it will be delivered and the most adequate route
of administration.
While antigen localization and immunization routes are
important aspects in eliciting a good immune response by
the host, the correct presentation of the antigen by L. lactis
to the antigen-presenting cells (APCs) is crucial if an effective
vaccine is to be developed.
1.2 Antigen modeling to optimize MHC priming
It has been calculated that from 104 degraded proteins only
1 peptide binds to the MHC class I molecule [13]. This is a
very modest amount of peptide compared with the massive
amounts of antigen available when L. lactis is administered
and yet it is sufficient to cause the prophylactic and thera-
peutic effects [9,11]. Considering the ease with which genetic
manipulations can be made in L. lactis, including the ability
to express the antigen in different cellular locations, it may
be possible to confer desirable characteristics to antigens to
be produced by the bacterium, resulting in a more effective
vaccine. This could involve the fusion of virus-derived or
bacteria-derived proteins to the antigen to facilitate MHC
I presentation. This can result in a better cellular immunity
response, as in previous experiments that have demon-
strated how fusing a protein from bacterial origin (e.g., a
domain from a toxin) to a particular antigen, results in an
increment in the immunogenicity and an augmentation in
the immune response. These experiments nevertheless,
were performed employing DNA vaccines to produce the
chimeric antigen [14-17]. Using adenoviral vectors, we have
demonstrated that the fusion of peptides commonly found
in the endoplasmic reticulum (ER) (e.g., calreticulin) to
an antigen, resulted in the retention of the antigen in the
ER, improving its presentation to the MHC I [18]. These
experiments indicate that enhanced antigen presentation
to the MHC I results in a better cellular immune
response [17-19]. Taking in account these results, it is possi-
ble to use the same strategy and, for example, fusing calre-
ticulin to antigens expressed by L. lactis in order to increase
the immunogenicity. Alternatively, also to increase the anti-
genicity and obtain a more robust immune response, mole-
cules capable of tight binding to APCs like dendritic cells
(e.g., bacterial heat shock proteins) may be fused to the
antigen of interest, as has been shown [15,16]. Such
approaches in the design of immunomodulatory proteins
or antigens expressed by L. lactis would result in a more
acute immune response since they would be tailor-
made to the type of immunity, when either humoral or
cellular immunity is desired.
Currently, the immunological responses evoked by geneti-
cally manipulated strains of L. lactis have achieved in the
majority of the cases, humoral responses in animal models [3].
In these cases, the immunization, with strains of L. lactis able
to produce a specific antigen results in the development of
specific antibodies against the pathogen (the causal agent)
and the alleviation of the disease [9,20].
Upon immunization, the genetically engineered L. lactis
should express the antigen, retain antigen already syn-
thesized or both. At some point the antigens (or fragments
of them) are internalized by APCs and loaded into the
endosomal compartment to the MHC II, where they are
later transported to the cell surface. The final outcome of
the above processes induce the generation of specific
antibodies, which later will recognize (and neutralize) the
causal agent and continue with the antibody-mediated
immune response. This humoral immunity resulting is
suitable for extracellular pathogens (e.g., bacteria, fungi
and protozoa).
But what about for other diseases where cell-mediated
immunity plays an essential role, like for example in the
case of virus infection and even more importantly, for
tumors? Is it possible to create a strategy using L. lactis
that will target cancerous cells and will act as an
anti-tumor agent?
In this context, it was demonstrated by Bermudez-
Humara´n and colleagues that immunization with a combi-
nation of two strains of L lactis expressing either E7 or
IL-12 resulted in both prophylactic and therapeutic effects
in a cervical cancer model [21]. In this report, it was dem-
onstrated how the E7 strain solely can confer (to a much
lesser extent) antitumoral activity. Moreover, very few
mice immunized with the non-expressing wild type strain
of L. lactis had tumors of similar size compared with the
group of mice immunized only with the strain expressing
E7. This suggests that either the vaccination with L. lactis
wild type alone may enhance at some level a non-
specific immune response that affected the growth of
the tumors, or that some of the mice vaccinated with
L. lactis-E7 did not respond to the treatment and the
tumor growth was similar as in the group vaccinated
with the non-expressing wild type strain. Nevertheless, in
this study it was demonstrated how an antigen-expressing
L. lactis is capable of inducing a cellular immune response
using simultaneously two strains of L. lactis expressing the
E7 antigen of the HPV and cellular-immunity activating
IL-12 [21].
2. Applying the technology of L. lactis for
current health issues
In emerging diseases, like the recent epidemic caused by the
H1N1 virus, the immediate availability (and distribution) of
a vaccine against a pathogen would have a tremendous effect
on the evolution and prevention of the epidemic. Unfortu-
nately, currently, after identifying the causal agent of an
emerging disease, the process to finally develop a safe and
functional vaccine (and make it commercially available) is
lengthy and tedious.
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For this reason, the existence of a ‘plug-in and ready-to-
produce’ vaccine using L. lactis could expedite the production
stage of a vaccine, and therefore, influence an ongoing
epidemic. Moreover, because preparation of growth medium
and cultures of L. lactis is relatively easy, the need for highly
skilled personnel is minimal and makes it advantageous to
proceed also in developing countries. Moreover, the route of
administration, either intranasal or oral, avoids the use of
infectious material, like needles and syringes commonly used
to apply non-oral vaccines, decreasing the risk of consequent
infections and reducing the cost of the vaccination. This
becomes attractive in situations where substantial numbers
of doses are needed in adverse conditions (environmental,
geographical or limited human resources).
In a previous case we mentioned that the immunization
with a genetically modified strain of L. lactis conferred protec-
tion to mice when they were challenged with the pathogen [9].
Using L. lactis, for example to develop a pneumococcal vac-
cine for humans, would prevent the need to use attenuated
strains of the pathogen intended to be used as a vaccine, or
lengthy and costly procedures to purify recombinant antigens
used for vaccination.
At the present time, a patented technology called
Actobiotics consists of biologically contained strains of
L. lactis able to secrete biological active interleukins in situ [22].
These strains of L. lactis are being employed to alleviate
inflammatory bowel disorders in humans (e.g., Crohn’s dis-
ease and ulcerative colitis). Actobiotics are delivered to
patients via oral administration (they are usually formulated
in capsules) avoiding the use of syringes and needles. This
technology is designed to selectively be delivered to receptors
and cells localized in the gastrointestinal tract, reducing the
exposure to non-target organs to a minimal (For detail infor-
mation of Actobiotics and its characteristics the reader is
referred to www.actogenix.com).
ActoGeniX, the company that exploits Actobiotics, has
completed Phase IIA of clinical trial to treat ulcerative colitis
in humans and is now in Phase I of a clinical trial to treat
oral mucositis in cancer patients using Actobiotics [Data
from ActoGeniX press release]. Safety is also an essential issue,
for that reason, ActoGeniX has also taken measures to prevent
undesired microbial endurance inside the host. This was
achieved by substituting an essential gene of L. lactis (thymi-
dylate synthase) with the gene of interest (IL-10) to prevent
prevalence of the genetically manipulated L. lactis once they
are released to the environment [7].
Another company focusing on the generation of vaccines
using L. lactis is Mucosis, who recently developed FluGEM,
an intranasal vaccine to prevent influenza. Moreover, this com-
pany deals with a novel variety of a non-genetically modified
strain of L. lactis, able to load antigens of viral, parasitic or bac-
terial origin on the cell envelope. The remarkable property of
the system named Mimopath is that the L. lactis cells loaded
with the antigen are administered dead, thus, the vaccine is
regarded as a non-genetically modified non-live vaccine [23,24].
3. Expert opinion and future perspective
The use of L. lactis as a therapeutic agent has been docu-
mented as safe and efficient, giving good results in a variety
of disease models. No side effects or undesired reactions
have been detected up to now. There have been only two
medical cases that reported L. lactis infection in humans, caus-
ing cardiovascular complications. The patients in these two
cases suffered from previous cardiac abnormalities. In one of
these patients the infection caused by L. lactis was firstly
treated with antibiotics. Once the infection was cleared, the
myoxoma, a possible pre-existing condition, was surgically
extirpated. After the surgery, the patient did not develop
any further infection with L. lactis [25]. These isolated two




Deletion of essential genes, auxotrophic strains [7]
Expression systems employed Constitutive expression, inducible systems




Intracellular antigen targeting (antigen fusion
with viral proteins, antigen-presenting cells binding proteins),
sub-cellular antigen retention (e.g., in the rugged
endoplasmic reticulum), immunomodulators
(interleukins, viral or heat shock proteins)
[14-18,21,29]
Increasing protein expression Codon optimization for Lactococcus, synthetic
promoters, protease deficient strains
[30,31]
Route of administration Dependent on the immune response most adequate
for the targeted disease and the entry route of the causal agent
[3]
Antigen location in L. lactis Cytoplasmic, extracellular or associated with the cell [11]
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cases probably represent opportunistic infection of (in this
case) L. lactis, due to the weakened general health of the
patients [25,26]. To our knowledge no cases of infection by
L. lactis have been reported in healthy individuals. This two
incidents involving opportunistic infection by L. lactis in
patients with deteriorated health should not discourage fur-
ther use of L. lactis in clinical trials or in any other medically
related research.
The application of L. lactis as a vaccine and therapeutic ele-
ment is a viable option that can be used safely, and even more
importantly, that can be developed rapidly to provide func-
tional and effective vaccines in newly emerging diseases and
world wide epidemics. The use of L. lactis as an established
vaccine could be achieved by the creation of a ‘ready-to-use’
reliable system that allows the rapid integration of the
antigen-coding DNA in L. lactis to provide an expeditious
vaccine whenever is required, for example in emerging epi-
demics or when large amounts of vaccines are required in
very little time.
Presently it is possible to optimize expression levels and
overall protein production using synthetic biology for
example with dual codon optimization, strong synthetic
promoters or synthetic genes. This and other considerations
are reviewed in Table 1, where the different present alterna-
tives to achieve an efficient vaccine using L. lactis are
also highlighted.
The low cost of the overall production of the vaccine when
L. lactis is employed is an advantage that would allow
developing countries to have access to vaccines and therapies
that usually are expensive and scarce. A few examples are the
availability of vaccines for tuberculosis, against HPV or for
pneumonia using L. lactis in countries where the prevalence
of these diseases is high (usually in countries with a large
population with low income per capita), could decrease the
number of current pandemics that have persisted for decades
due to the lack of commercial available vaccines that are
readily accessible for the population.
In less than 5 years the use of L. lactis in clinical trials pro-
gressed from Phase I to Phase IIA (Table 2). There is also an
ongoing clinical trial Phase IB to treat oral mucositis in cancer
patients, using this same therapeutic agent. Other pre-clinical
trials are currently being prepared to treat celiac disease,
type 1 and 2 diabetes, and allergic diseases (Data from Acto-
GeniX press release), as well as the development of a pneumo-
coccal vaccine (Mucosis) [27]. With this, there are precedents
that encourage and support further applications of L. lactis
to alleviate other diseases.
In the coming years it will be important that scientists sup-
porting the use of L. lactis as a therapeutic agent transfer their
achievements to endorsed proposals for clinical trials in
humans to provide more evidence for future successful appli-
cations, ultimately culminating in the use of L. lactis as a com-
mercial available biopharmaceutical against any disease
of relevance.
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Table 2. List of clinical trials and diseases targeted with Lactococcus lactis.













Ulcerative colitis* Oral Digestive Live (biologically contained) IL-10 Phase II
Inflammatory bowel
disease (Crohn’s disease)*
Oral Digestive Live (biologically contained) IL-10 Phase I











*Obtained from ActoGeniX press release.
zObtained from Mucosis press release.
Villatoro-Hernandez, Montes-de-Oca-Luna & Kuipers




























































Paper of special note have been highlighted as
either of interest () or of considerable interest
() to readers.
1. Bermudez-Humaran LG. Lactococcus
lactis as a live vector for mucosal delivery
of therapeutic proteins. Hum Vaccin
2009;4:264-7
2. Van Huynegem K, Loos M,
Steidler L. Immunomodulation
by genetically engineered lactic
acid bacteria. Front Biosci
2009;14:4825-35
3. Wells JM, Mercenier A.
Mucosal delivery of therapeutic and
prophylactic molecules using lactic
acid bacteria. Nat Rev Microbiol
2008;5:349-62
4. Iwaki M, Okahashi N, Takahashi I, et al.
Oral immunization with recombinant
Streptococcus lactis carrying the
Streptococcus mutans surface protein
antigen gene. Infect Immun
1990;58:2929-34
5. Mielcarek N, Alonso S, Locht C.
Nasal vaccination using live bacterial
vectors. Adv Drug Deliv Rev
2001;51:55-69
6. Braat H, Rottiers P, Hommes DW,
et al. A Phase I trial with
transgenic bacteria expressing
interleukin-10 in Crohn’s disease.
Clin Gastroenterol Hepatol
2006;4:754-9
.. This report, to our knowledge, is the
first clinical trial using a genetically
modified strain of L. lactis in humans.
7. Steidler L, Neirynck S, Huyghebaert N,
et al. Biological containment of
genetically modified Lactococcus lactis
for intestinal delivery of human
interleukin 10. Nat Biotechnol
2003;21:785-9
8. Vandenbroucke K, de Haard H,
Beirnaert E, et al. Orally administered
L. lactis secreting an anti-TNF
Nanobody demonstrate efficacy in
chronic colitis. Mucosal Immunol
2009;1:49-56
9. Hanniffy SB, Carter AT, Hitchin E,




infection. J Infect Dis
2007;195:185-93
10. de Ruyter PG, Kuipers OP,
de Vos WM. Controlled gene
expression systems for Lactococcus lactis
with the food-grade inducer nisin.
Appl Environ Microbiol 1996;62:3662-7
11. Bermudez-Humaran LG,
Cortes-Perez NG, Le Loir Y, et al.
An inducible surface presentation
system improves cellular immunity
against human papillomavirus
type 16 E7 antigen in mice after nasal
administration with recombinant
lactococci. J Med Microbiol
2004;53:427-33
12. Holmgren J, Czerkinsky C.
Mucosal immunity and vaccines.
Nat Med 2005;11:45-53
13. Yewdell JW. Not such a dismal science:
the economics of protein synthesis,
folding, degradation and antigen
processing. Trends Cell Biol
2001;11:294-7
14. Cuesta AM, Suarez E, Larsen M,
et al. Enhancement of DNA vaccine
potency through linkage of antigen to
filamentous bacteriophage coat protein
III domain I. Immunology
2006;117:502-6
15. Chen CH, Wang TL, Hung CF, et al.
Enhancement of DNA vaccine potency
by linkage of antigen gene to an
HSP70 gene. Cancer Res
2000;60:1035-42
16. Kim JW, Hung CF, Juang J, et al.
Comparison of HPV DNA
vaccines employing intracellular
targeting strategies. Gene Ther
2004;11:1011-18
17. Liao CW, Chen CA, Lee CN,
et al. Fusion protein vaccine by
domains of bacterial exotoxin linked
with a tumor antigen generates
potent immunologic responses and
antitumor effects. Cancer Res
2005;65:9089-98
18. Loera-Arias MJ, Martinez-Perez AG,
Barrera-Hernandez A, et al. Targeting
and retention of HPV16 E7 to the
endoplasmic reticulum enhances immune
tumour protection. J Cell Mol Med
2010;14:890-4
19. Hung CF, Monie A, Alvarez RD, et al.
DNA vaccines for cervical cancer: from
bench to bedside. Exp Mol Med
2007;39:679-89
20. Lee P, Faubert GM. Expression of the




Cortes-Perez NG, Lefevre F, et al.
A novel mucosal vaccine based on live
Lactococci expressing E7 antigen and
IL-12 induces systemic and mucosal
immune responses and protects mice
against human papillomavirus
type 16-induced tumors. J Immunol
2005;175:7297-302
22. Steidler L, Rottiers P, Coulie B.
Actobiotics as a novel method for
cytokine delivery. Ann NY Acad Sci
2009;1182:135-45
23. Bosma T, Kanninga R, Neef J, et al.
Novel surface display system for proteins
on non-genetically modified
Gram-positive bacteria.
Appl Environ Microbiol 2006;72:880-9
24. van Roosmalen ML, Kanninga R,
El Khattabi M, et al. Mucosal vaccine
delivery of antigens tightly bound to an
adjuvant particle made from food-grade
bacteria. Methods 2006;38:144-9
25. Zechini B, Cipriani P, Papadopoulou S,
et al. Endocarditis caused by Lactococcus
lactis subsp. lactis in a patient with atrial
myxoma: a case report. Diagn Microbiol
Infect Dis 2006;56:325-8
26. Pellizzer G, Benedetti P, Biavasco F,
et al. Bacterial endocarditis due to
Lactococcus lactis subsp. cremoris: case
report. Clin Microbiol Infect
1996;2:230-2
27. Audouy SA, van Selm S,
van Roosmalen ML, et al. Development
of lactococcal GEM-based pneumococcal
vaccines. Vaccine 2007;25:2497-506
28. Mierau I, Kleerebezem M. 10 years of
the nisin-controlled gene expression
system (NICE) in Lactococcus lactis.
Appl Microbiol Biotechnol
2005;68:705-17
29. Kang TH, Kim KW, Bae HC, et al.
Enhancement of DNA vaccine potency
by antigen linkage to
IFN-gamma-inducible protein-10. Int J
Cancer 2010, doi: 10.1002/ijc.25391
30. Fuglsang A. Lactic acid bacteria as prime
candidates for codon optimization.
Biochem Biophys Res Commun
2003;312:285-91
Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation



























































31. Mijakovic I, Petranovic D, Jensen PR.
Tunable promoters in systems biology.










Kerklaan 30, 9751 NN, Haren,
The Netherlands
Tel: +31 50 363 2107; Fax: +31 50 363 2348;
E-mail: j.villatoro.hernandez@rug.nl




Universidad Auto´noma de Nuevo Leo´n,
Madero y Aguirre Pequen˜o S/N,
Monterrey, Nuevo Leo´n,
Me´xico 64460
Villatoro-Hernandez, Montes-de-Oca-Luna & Kuipers
Expert Opin. Biol. Ther. (2011) 11(3) 267
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f G
ro
ni
ng
en
 o
n 
02
/2
3/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
